Background: Carcinoid heart disease (CHD) is common in patients with carcinoid syndrome (CS). Surgical treatment improves the poor prognosis of CHD, although the reported peri-operative mortality is high (∼17%). We attempted to improve outcomes by implementation of a protocol for the management of patients with CHD at a UK Neuroendocrine Centre of Excellence and report our experience. Methods: All patients treated for CHD between 2008 and 2015 were included. Peri-operative treatment included surgical features such as invasive pulmonary valve (PV) inspection and preservation of the tricuspid subvalvular apparatus. Results: A total of 11 patients were treated; the median age was 63 years (IQR: 56-70). Ten patients underwent both pulmonary valve replacement (PVR) and tricuspid valve replacement (TVR); 1 patient underwent isolated TVR. One patient had additional aortic valve replacement (AVR), another one coronary artery bypass grafting. Bioprostheses (BP) were used in all patients, stented for TVR and AVR, stentless for PVR. Invasive PV inspection caused unplanned PVR in 3 cases (27.3%). All patients were discharged home. One patient (9.1%), who had had previous TVR by another surgeon, had right heart failure (RHF) during follow-up. One death occurred due to progression of CS (day 346). The carcinoids' primary was resected in 5 patients (45.5%) 10 months (4.5-19.5) after cardiac surgery. Conclusion: Excellent results were achieved in patients with CHD. PV stenosis can be underestimated by echocardiography; therefore, intraoperative inspection is recommended. Right ventricular geometry should be respected to prevent RHF. BP should be used, as these patients are likely to undergo future non-cardiac surgeries.

Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumours. Cancer 1997;79:813-829.
Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196.
Grozinsky-Glasberg S, Grossman AB, Gross DJ: Carcinoid heart disease: from pathophysiology to treatment - ‘something in the way it moves'. Neuroendocrinology 2015;101:263-273.
Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV: Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 2002;77:139-147.
Manoly I, McAnelly SL, Sriskandarajah S, McLaughlin KE: Prognosis of patients with carcinoid heart disease after valvular surgery. Interact Cardiovasc Thorac Surg 2014;19:302-305.
Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J: Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg 2011;40:168-172.
Komoda S, Komoda T, Pavel ME, Morawietz L, Wiedenmann B, Hetzer R, Lehmkuhl HB: Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg 2011;59:780-785.
Schaefer A, Sill B, Schoenebeck J, Schneeberger Y, Reichenspurner H, Gulbins H: Failing stentless bioprostheses in patients with carcinoid heart valve disease. J Cardiothorac Surg 2015;10:41.
Fries R, Wendler O, Schieffer H, Schäfers HJ: Comparative rest and exercise hemodynamics of 23-mm stentless versus 23-mm stented aortic bioprostheses. Ann Thorac Surg 2000;69:817-822.
Castillo JG, Silvay G, Solís J: Current concepts in diagnosis and perioperative management of carcinoid heart disease. Semin Cardiothorac Vasc Anesth 2013;17:212-223.
Shen C, Shih YT, Xu Y, Yao JC: Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer 2014;120:2039-2049.
Mabvuure N, Cumberworth A, Hindocha S: In patients with carcinoid syndrome undergoing valve replacement: will a biological valve have acceptable durability? Interact Cardiovasc Thorac Surg 2012;15:467-471.
Conradi L, Schaefer A, Mueller GC, Seiffert M, Gulbins H, Blankenberg S Reichenspurner H, Treede H, Diemert P: Carcinoid heart valve disease: transcatheter pulmonary valve-in-valve implantation in failing biological xenografts. J Heart Valve Dis 2015;24:110-114.
Conradi L, Silaschi M, Seiffert M, Lubos E, Blankenberg S, Reichenspurner H, Schaefer U, Treede H: Transcatheter valve-in-valve therapy using 6 different devices in 4 anatomic positions: clinical outcomes and technical considerations. J Thorac Cardiovasc Surg 2015;150:1557-1567.e3.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.